GlassScriptPhysician profile
Nicholas Mahr
NPI 1003923780
$606.44
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $16.84 · 2021: $111 · 2022: $161.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $203.66 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.18 | 2022 | |
| Amgen INC. | $71.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.16 | 2022 | |
| Novartis Pharmaceuticals Corporation | $42.05 | 2021 | |
| Chiesi USA, INC. | $36.63 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $32.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.03 | 2019 | |
| Edwards Lifesciences Corporation | $16.84 | 2020 | |
| Boston Scientific Corporation | $13.86 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.86 | 2022 | |
| Medtronic, INC. | $12.80 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Mahr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.